CVRx (CVRX) EBIT per Share : $-2.35 (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is CVRx EBIT per Share?

CVRx's EBIT per Share for the three months ended in Mar. 2024 was $-1.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.35.

During the past 3 years, the average EBIT per Share Growth Rate was 59.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for CVRx's EBIT per Share or its related term are showing as below:

CVRX' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -28.1 Med: 15.8 Max: 59.7
Current: 59.7

During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of CVRx was 59.70% per year. The lowest was -28.10% per year. And the median was 15.80% per year.

CVRX's 3-Year EBIT Growth Rate is ranked better than
93.54% of 727 companies
in the Medical Devices & Instruments industry
Industry Median: 5.9 vs CVRX: 59.70

CVRx's EBIT for the three months ended in Mar. 2024 was $-21.19 Mil.

CVRx EBIT per Share Historical Data

The historical data trend for CVRx's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CVRx EBIT per Share Chart

CVRx Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-1.24

-31.83

-3.94

-2.00

-1.89

CVRx Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial													-0.54	-0.54	-0.41	-0.41	-1.00

CVRx EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

CVRx's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-39.253	/	20.754
=	-1.89

CVRx's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-21.188	/	21.232
=	-1.00

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.35

CVRx (NAS:CVRX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

CVRx EBIT per Share Related Terms

Thank you for viewing the detailed overview of CVRx's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

CVRx (CVRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CVRx Inc (NAS:CVRX) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

9201 West Broadway Avenue, Suite 650, Minneapolis, MN, USA, 55445

Website

https://www.cvrx.com

CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.

Executives

Johnson & Johnson Innovation - Jjdc, Inc.	10 percent owner	410 GEORGE STREET, NEW BRUNSWICK NJ 08901
Paul Verrastro	officer: Chief Marketing Officer	9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Kevin Hykes	director	2 GOODYEAR, SUITE B, IRVINE CA 92618
Kirk G. Nielsen	director	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Mudit K. Jain	director	C/O TREO VENTURES, 140 WASHINGTON STREET, SUITE 200, RENO NV 89503
Craig E. Palmer	officer: SVP, U.S. Sales	9201 WEST BROADWAY AVENUE, SUITE 650, MINNEAPOLIS MN 55445
Martha Shadan	director	9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
New Enterprise Associates 10 L P	10 percent owner
Nea Partners 10 L P	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Geoffrey B Pardo	director	100 DOMAIN DRIVE, EXETER NH 03833
Jared Oasheim	officer: Chief Financial Officer	9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
John Brintnall	officer: Chief Strategy Officer and Sec	9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Dean Bruhn-ding	officer: VP of Reg. Affairs and QA	9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Liz Galle	officer: VP of Global Clinical Research	9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Nadim Yared	director, officer: Chief Executive Officer	9201 W BROADWAY AVE #650, MINNEAPOLIS MN 55445